Eidos治疗(EIDX)

122.21 0.00 0.0%

今开:0.0昨收:122.21
最高:0.0 最低:0.0
涨停价:0.0跌停价:0.0
总市值:4.74931561E9

Eidos治疗的热门评论

chuminhua2020-12-15 11:33

12/14,据彭博社援引匿名消息来源的报道称,Eidos Therapeutics于11月收到葛兰素史克(GlaxoSmithKline)的收购要约。Eidos已经同意BridgeBio Pharma的收购要约,该公司在最近的一份文件中披露,“大型国际制药公司”在11月下旬以每股120美元的全现金,无约束力的出价竞标了Eidos。
据彭博社报...查看全文

Eidos治疗(EIDX)2020-03-31 04:30

$Eidos治疗(EIDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-009640 Size: 10 KB 网页链接查看全文

Eidos治疗(EIDX)2020-03-24 18:15

$Eidos治疗(EIDX)$ 8-K Current report, item 8.01 Accession Number: 0001193125-20-083086 Act: 34 Size: 32 KB 网页链接查看全文

Eidos治疗(EIDX)2020-03-05 05:15

$Eidos治疗(EIDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-006944 Size: 10 KB 网页链接查看全文

Eidos治疗(EIDX)2020-02-27 05:40

$Eidos治疗(EIDX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001564590-20-006810 Act: 34 Size: 439 KB 网页链接查看全文

Eidos治疗(EIDX)2020-03-05 05:15

$Eidos治疗(EIDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-006941 Size: 5 KB 网页链接查看全文

Eidos治疗(EIDX)2020-02-27 05:50

$Eidos治疗(EIDX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001564590-20-006823 Act: 34 Size: 12 MB 网页链接查看全文

Eidos治疗(EIDX)2020-02-19 19:15

$Eidos治疗(EIDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-005000 Size: 7 KB 网页链接查看全文

Eidos治疗(EIDX)2020-02-06 05:15

$Eidos治疗(EIDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-003247 Size: 15 KB 网页链接查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Eidos治疗的最新评论

Eidos治疗(EIDX)2019-02-22 09:40

$Eidos治疗(EIDX)$ 8-K - Current report Filed: 2019-02-21 AccNo: 0001193125-19-046278 Size: 27 KBItem 4.01: Changes in Registrant's Certifying AccountantItem 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review ...查看全文

Eidos治疗(EIDX)2019-01-11 09:10

$Eidos治疗(EIDX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-01-10 AccNo: 0000903423-19-000020 Size: 134 KB 网页链接查看全文

群氓鄙陋2018-11-13 23:56

$Eidos Therapeutics(EIDX)$$Scholar Rock Holding(SRRK)$ 依然比较坚挺,另一只就有点歇菜了查看全文

淘沙见金2018-11-11 01:08

$Eidos Therapeutics(EIDX)$ 非常不错的数据! AG10 Resulted in Average TTR Stabilization Greater than 90% in All Actively Treated Subjects at Day 28. AG10 Significantly Raised Serum TTR Concentrations (p<0.0001) by 50% and 36% in Subjects Administered 800 mg Twice Daily and ...查看全文

2018年11月重点关注标的

greenlandbiotech2018-10-24 03:34

这一次11月的重点关注标的我们特意提前发布,主要是最近市场对小市值药股无论positive还是negative的消息都进行卖空的行为,使得我们需要去适应市场的改变,因此,更建议大家更早的投资那些有着爆点的且值得投资的标的,我们重点推荐关注NASH市场的VKTX(12号) MDGL(12号) GLMD(13号)在11月...查看全文

淘沙见金2018-08-28 20:05

$Eidos Therapeutics(EIDX)$ $辉瑞(PFE)$ 对数据分析的比较详细[牛][牛][牛]查看全文

淘沙见金2018-08-27 22:45

$Eidos Therapeutics, Inc.(EIDX)$ The data seem almost a worse case for EIDX (will be interesting to see their management spin). $辉瑞(PFE)$ had good efficacy and so set the bar high for a drug with a similar MOA. In addition, the lack of a dose response undermines the EIDX ar...查看全文

IPO公司简析-Eidos Therapeutics

淘沙见金2018-08-19 12:37

(原文发表地址: 网页链接,本文在原文的基础上有更新)Eidos Therapeutics ($Eidos Therapeutics(EIDX)$ )是一家临床阶段的生物制药公司,专注于解决由转甲状腺素蛋白(transthyretin,TTR)淀粉样变性(amyloidosis,ATTR)引发的疾病。公司新股的发行价15.00-17.00...查看全文

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Eidos治疗的公告

$Eidos治疗(EIDX)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-21-017733 Size: 29 KB 网页链接

$Eidos治疗(EIDX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-21-003286 Size: 7 KB 网页链接

$Eidos治疗(EIDX)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001193125-21-017696 Act: 33 Size: 22 KB 网页链接

$Eidos治疗(EIDX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-017697 Act: 33 Size: 23 KB 网页链接

$Eidos治疗(EIDX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-017698 Act: 33 Size: 23 KB 网页链接

$Eidos治疗(EIDX)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-21-017699 Act: 33 Size: 23 KB 网页链接

$Eidos治疗(EIDX)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-21-017128 Act: 34 Size: 33 KB 网页链接

$Eidos治疗(EIDX)$ 8-K Current report, items 1.01, 2.01, 2.03, 3.01, 3.03, 5.01, 5.02, 5.03, and 9.01 Accession Number: 0001193125-21-017109 Act: 34 Size: 381 KB 网页链接

$Eidos治疗(EIDX)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-21-000105 Act: 34 Size: 2 KB 网页链接

$Eidos治疗(EIDX)$ 8-K Current report, items 5.07, 8.01, and 9.01 Accession Number: 0001193125-21-012447 Act: 34 Size: 208 KB 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15